Roche Holding AG (RHHBY.PK) Monday announced that the United States Food and Drug Administration, or the US FDA, has approved a new HIV viral load test.
The research-focused healthcare company stated that the new HIV viral load test targets two highly conserved regions of the HIV-1 genome and avoids any regions which are current drug targets, thus providing increased reliability as compared to other single target assays should a mutation occur.
Roche further added that the new HIV viral load test will be commercially available later this calendar year.
"The approval of the Roche HIV test expands the availability to more laboratories, clinicians and patients," said Paul Brown, PhD, Head of Roche Molecular Diagnostics. "Roche is committed to developing new diagnostic tools such as this highly innovative HIV 'dual target' test to help improve the ability of physicians to monitor viral load and properly treat people living with HIV."
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.